Showing 4811-4820 of 8859 results for "".
- Dove, Conservation International Announce Million Dollar Forest Restoration Project to Fight Climate Changehttps://practicaldermatology.com/news/dove-conservation-international-announce-million-dollar-forest-restoration-project-to-fight-climate-change/2460822/Dove is launching the Dove Forest Restoration Project, one of the biggest protection and restoration efforts from any beauty brand to-date. The project is designed to protect and restore forests, protect the habitats of endangered species, and improve the livelihoods of 16,000 peo
- AstraZeneca's Anifrolumab Shows Benefit for Skin, Joint Symptoms of Lupushttps://practicaldermatology.com/news/astrazenecas-anifrolumab-shows-benefit-for-skin-joint-symptoms-of-lupus/2460819/Anifrolumab is consistently associated with improvements in both skin rash and arthritis across three different disease measures in patients with moderate to severe systemic lupus erythematosus (SLE), results of a new post-hoc analysis of pooled data from the TULIP phase 3 clinical trials show. T
- AADA Statement on Legislative Interference in Health Care for Transgender Patientshttps://practicaldermatology.com/news/aada-statement-on-legislative-interference-in-health-care-for-transgender-patients/2460817/The American Academy of Dermatology Association strongly opposes recent efforts by state legislatures to restrict physicians’ ability to provide care to transgender youths. Legislation such as the bill enacted this spring in Arkansas as well as those proposed in several other states are a d
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers/2460816/Henry H.L. Chan, MD, PhD, FRCP, is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Chan is currently the Honorary Clinical Professor and Honorary Consultant Dermatologist of the Division of Dermatology, Department of Medicine, The University of Hong
- Cosentyx Now Approved for Psoriasis in Children as Young as Sixhttps://practicaldermatology.com/news/cosentyx-now-approved-for-psoriasis-in-children-as-young-as-six/2460815/Cosentyx® (secukinumab) from Novartis is now FDA approved for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the U
- Bliss Becomes First Mass & Drug Skincare Brand to Receive B Corp Certificationhttps://practicaldermatology.com/news/bliss-becomes-first-mass-drug-skincare-brand-to-receive-b-corp-certification/2460814/Bliss is the first-ever skincare brand sold at mass and drug to achieve B Corp Certification. This certification confirms that Bliss meets the highest standards of verified social and environmental performance, public transparency, and legal accountability to balance pr
- AAD Survey: Americans Are Confused About Sunscreen Usehttps://practicaldermatology.com/news/aad-survey-americans-are-confused-about-sunscreen-use/2460812/Your patients likely need a refresher course on sunscreen application and SPF. This is the main takeaway message of a recent survey of 1,000 U.S. adults by the American Academy of Dermatology. While 80 percent of Americans know they should apply sunscreen every two hours when outdoors,
- Dermatological Agents, NSAIDs Are Leading Prescription Cost Drivers in New 28-State WCRI Drug Trends Studyhttps://practicaldermatology.com/news/dermatological-agents-nsaids-are-leading-prescription-cost-drivers-in-new-28-state-wcri-drug-trends-study/2460809/In most states, dermatological agents accounted for about 20 percent of total prescription payments in the first quarter of 2020 (2020Q1), according to a
- Indoor Tanning Linked to Anxiety, Depressionhttps://practicaldermatology.com/news/indoor-tanning-linked-to-anxiety-depression/2460808/Indoor tanning early in life is associated with risk of anxiety and depression later in life, according to new research in the Journal of the American Academy of Dermatology. Excluding women wi
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas